CONOTOXINS
A substantially pure conotoxin which is highly selective for a specific human receptor, which conotoxin is selected from the group consisting of: Glu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro- Tyr-Ile-Leu (SEQ ID NO:13) wherein Glu in the 1-position is pGlu and the C-terminus is amidated; Gly-...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ABOGADIE, FE OLIVERA, BALDOMERO M HOPKINS, CHRIS E RIVIER, JEAN E.F DYKERT, JOHN TORRES, JOSEP L CRUZ, LOURDES J |
| description | A substantially pure conotoxin which is highly selective for a specific human receptor, which conotoxin is selected from the group consisting of: Glu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro- Tyr-Ile-Leu (SEQ ID NO:13) wherein Glu in the 1-position is pGlu and the C-terminus is amidated; Gly-Glu-Xaa-Xaa-Va1-Ala-Lys-Met-Ala-Ala-Xaa-Leu-Ala- Arg-Xaa-Asn-Ile-Ala-Lys-Gly-Cys-Lys-Val-Asn-Cys-Tyr- Pro (SEQ ID NO:12) wherein Xaa is Gla; Ser-Thr-Ser-Cys-Met-Glu-Ala-Gly-Ser-Tyr-Cys-Gly-Ser- Thr-Thr-Arg-Ile-Cys-Cys-Gly-Tyr-Cys-Ala-Tyr-Phe-Gly- Lys-Lys-Cys-Ile-Asp-Tyr-Pro-Ser-Asn (SEQ ID NO:11); Cys-Lys-Thr-Tyr-Ser-Lys-Tyr-Cys-Xaa-Ala-Asp-Ser-Xaa- Cys-Cys-Thr-Xaa-Gln-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu- Phe (SEQ ID NO:10) wherein Xaa is Gla and the C-terminus is amidated; His-Xaa-Xaa-Cys-Cys-Leu-Tyr-Gly-Lys-Cys-Arg-Arg-Tyr- Xaa-Gly-Cys-Ser- Ser-Ala-Ser-Cys-Cys-Gln (SEQ ID NO:9) wherein Xaa is 4Hyp; Gly-Cys-Cys-Ser-His-Pro-Ala-Cys-Ser-Gly-Lys-Tyr-Gln- Xaa-Tyr-Cys-Arg- Xaa- Ser (SEQ ID NO:8) wherein Xaa is Gla and the C-terminus is amidated; and Gly-Xaa-Ser-Phe-Cys-Lys-Ala-Asp-Glu-Lys-Xaa-Cys-Glu- Tyr-His-Ala-Asp-Cys-Cys-Asn-Cys-Cys-Leu-Ser-Gly-Ile- Cys-Ala-Xaa-Ser-Thr-Asn-Trp-Ile-Leu-Pro-Gly-Cys-Ser- Thr-Ser-Ser-Phe-Phe-Lys-Ile (SEQ ID NO:7) wherein Xaa is 4Hyp. These conotoxins may be used to prepare medicaments for the treatment of neuromuscular disorders. Some may be used for rapid reversible immobilisation of muscles or for diagnosing myasthenia gravis or Lambert-Eaton myasthenic syndrome. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2420184C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2420184C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2420184C3</originalsourceid><addsrcrecordid>eNrjZOBy9vfzD_GP8PQL5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORiZGBoYWJs7GhFUAAP4DGxU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CONOTOXINS</title><source>esp@cenet</source><creator>ABOGADIE, FE ; OLIVERA, BALDOMERO M ; HOPKINS, CHRIS E ; RIVIER, JEAN E.F ; DYKERT, JOHN ; TORRES, JOSEP L ; CRUZ, LOURDES J</creator><creatorcontrib>ABOGADIE, FE ; OLIVERA, BALDOMERO M ; HOPKINS, CHRIS E ; RIVIER, JEAN E.F ; DYKERT, JOHN ; TORRES, JOSEP L ; CRUZ, LOURDES J</creatorcontrib><description>A substantially pure conotoxin which is highly selective for a specific human receptor, which conotoxin is selected from the group consisting of: Glu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro- Tyr-Ile-Leu (SEQ ID NO:13) wherein Glu in the 1-position is pGlu and the C-terminus is amidated; Gly-Glu-Xaa-Xaa-Va1-Ala-Lys-Met-Ala-Ala-Xaa-Leu-Ala- Arg-Xaa-Asn-Ile-Ala-Lys-Gly-Cys-Lys-Val-Asn-Cys-Tyr- Pro (SEQ ID NO:12) wherein Xaa is Gla; Ser-Thr-Ser-Cys-Met-Glu-Ala-Gly-Ser-Tyr-Cys-Gly-Ser- Thr-Thr-Arg-Ile-Cys-Cys-Gly-Tyr-Cys-Ala-Tyr-Phe-Gly- Lys-Lys-Cys-Ile-Asp-Tyr-Pro-Ser-Asn (SEQ ID NO:11); Cys-Lys-Thr-Tyr-Ser-Lys-Tyr-Cys-Xaa-Ala-Asp-Ser-Xaa- Cys-Cys-Thr-Xaa-Gln-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu- Phe (SEQ ID NO:10) wherein Xaa is Gla and the C-terminus is amidated; His-Xaa-Xaa-Cys-Cys-Leu-Tyr-Gly-Lys-Cys-Arg-Arg-Tyr- Xaa-Gly-Cys-Ser- Ser-Ala-Ser-Cys-Cys-Gln (SEQ ID NO:9) wherein Xaa is 4Hyp; Gly-Cys-Cys-Ser-His-Pro-Ala-Cys-Ser-Gly-Lys-Tyr-Gln- Xaa-Tyr-Cys-Arg- Xaa- Ser (SEQ ID NO:8) wherein Xaa is Gla and the C-terminus is amidated; and Gly-Xaa-Ser-Phe-Cys-Lys-Ala-Asp-Glu-Lys-Xaa-Cys-Glu- Tyr-His-Ala-Asp-Cys-Cys-Asn-Cys-Cys-Leu-Ser-Gly-Ile- Cys-Ala-Xaa-Ser-Thr-Asn-Trp-Ile-Leu-Pro-Gly-Cys-Ser- Thr-Ser-Ser-Phe-Phe-Lys-Ile (SEQ ID NO:7) wherein Xaa is 4Hyp. These conotoxins may be used to prepare medicaments for the treatment of neuromuscular disorders. Some may be used for rapid reversible immobilisation of muscles or for diagnosing myasthenia gravis or Lambert-Eaton myasthenic syndrome.</description><edition>7</edition><language>eng ; fre</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2004</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040921&DB=EPODOC&CC=CA&NR=2420184C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20040921&DB=EPODOC&CC=CA&NR=2420184C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ABOGADIE, FE</creatorcontrib><creatorcontrib>OLIVERA, BALDOMERO M</creatorcontrib><creatorcontrib>HOPKINS, CHRIS E</creatorcontrib><creatorcontrib>RIVIER, JEAN E.F</creatorcontrib><creatorcontrib>DYKERT, JOHN</creatorcontrib><creatorcontrib>TORRES, JOSEP L</creatorcontrib><creatorcontrib>CRUZ, LOURDES J</creatorcontrib><title>CONOTOXINS</title><description>A substantially pure conotoxin which is highly selective for a specific human receptor, which conotoxin is selected from the group consisting of: Glu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro- Tyr-Ile-Leu (SEQ ID NO:13) wherein Glu in the 1-position is pGlu and the C-terminus is amidated; Gly-Glu-Xaa-Xaa-Va1-Ala-Lys-Met-Ala-Ala-Xaa-Leu-Ala- Arg-Xaa-Asn-Ile-Ala-Lys-Gly-Cys-Lys-Val-Asn-Cys-Tyr- Pro (SEQ ID NO:12) wherein Xaa is Gla; Ser-Thr-Ser-Cys-Met-Glu-Ala-Gly-Ser-Tyr-Cys-Gly-Ser- Thr-Thr-Arg-Ile-Cys-Cys-Gly-Tyr-Cys-Ala-Tyr-Phe-Gly- Lys-Lys-Cys-Ile-Asp-Tyr-Pro-Ser-Asn (SEQ ID NO:11); Cys-Lys-Thr-Tyr-Ser-Lys-Tyr-Cys-Xaa-Ala-Asp-Ser-Xaa- Cys-Cys-Thr-Xaa-Gln-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu- Phe (SEQ ID NO:10) wherein Xaa is Gla and the C-terminus is amidated; His-Xaa-Xaa-Cys-Cys-Leu-Tyr-Gly-Lys-Cys-Arg-Arg-Tyr- Xaa-Gly-Cys-Ser- Ser-Ala-Ser-Cys-Cys-Gln (SEQ ID NO:9) wherein Xaa is 4Hyp; Gly-Cys-Cys-Ser-His-Pro-Ala-Cys-Ser-Gly-Lys-Tyr-Gln- Xaa-Tyr-Cys-Arg- Xaa- Ser (SEQ ID NO:8) wherein Xaa is Gla and the C-terminus is amidated; and Gly-Xaa-Ser-Phe-Cys-Lys-Ala-Asp-Glu-Lys-Xaa-Cys-Glu- Tyr-His-Ala-Asp-Cys-Cys-Asn-Cys-Cys-Leu-Ser-Gly-Ile- Cys-Ala-Xaa-Ser-Thr-Asn-Trp-Ile-Leu-Pro-Gly-Cys-Ser- Thr-Ser-Ser-Phe-Phe-Lys-Ile (SEQ ID NO:7) wherein Xaa is 4Hyp. These conotoxins may be used to prepare medicaments for the treatment of neuromuscular disorders. Some may be used for rapid reversible immobilisation of muscles or for diagnosing myasthenia gravis or Lambert-Eaton myasthenic syndrome.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2004</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZOBy9vfzD_GP8PQL5mFgTUvMKU7lhdLcDPJuriHOHrqpBfnxqcUFicmpeakl8c6ORiZGBoYWJs7GhFUAAP4DGxU</recordid><startdate>20040921</startdate><enddate>20040921</enddate><creator>ABOGADIE, FE</creator><creator>OLIVERA, BALDOMERO M</creator><creator>HOPKINS, CHRIS E</creator><creator>RIVIER, JEAN E.F</creator><creator>DYKERT, JOHN</creator><creator>TORRES, JOSEP L</creator><creator>CRUZ, LOURDES J</creator><scope>EVB</scope></search><sort><creationdate>20040921</creationdate><title>CONOTOXINS</title><author>ABOGADIE, FE ; OLIVERA, BALDOMERO M ; HOPKINS, CHRIS E ; RIVIER, JEAN E.F ; DYKERT, JOHN ; TORRES, JOSEP L ; CRUZ, LOURDES J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2420184C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2004</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>ABOGADIE, FE</creatorcontrib><creatorcontrib>OLIVERA, BALDOMERO M</creatorcontrib><creatorcontrib>HOPKINS, CHRIS E</creatorcontrib><creatorcontrib>RIVIER, JEAN E.F</creatorcontrib><creatorcontrib>DYKERT, JOHN</creatorcontrib><creatorcontrib>TORRES, JOSEP L</creatorcontrib><creatorcontrib>CRUZ, LOURDES J</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ABOGADIE, FE</au><au>OLIVERA, BALDOMERO M</au><au>HOPKINS, CHRIS E</au><au>RIVIER, JEAN E.F</au><au>DYKERT, JOHN</au><au>TORRES, JOSEP L</au><au>CRUZ, LOURDES J</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CONOTOXINS</title><date>2004-09-21</date><risdate>2004</risdate><abstract>A substantially pure conotoxin which is highly selective for a specific human receptor, which conotoxin is selected from the group consisting of: Glu-Ser-Glu-Glu-Gly-Gly-Ser-Asn-Ala-Thr-Lys-Lys-Pro- Tyr-Ile-Leu (SEQ ID NO:13) wherein Glu in the 1-position is pGlu and the C-terminus is amidated; Gly-Glu-Xaa-Xaa-Va1-Ala-Lys-Met-Ala-Ala-Xaa-Leu-Ala- Arg-Xaa-Asn-Ile-Ala-Lys-Gly-Cys-Lys-Val-Asn-Cys-Tyr- Pro (SEQ ID NO:12) wherein Xaa is Gla; Ser-Thr-Ser-Cys-Met-Glu-Ala-Gly-Ser-Tyr-Cys-Gly-Ser- Thr-Thr-Arg-Ile-Cys-Cys-Gly-Tyr-Cys-Ala-Tyr-Phe-Gly- Lys-Lys-Cys-Ile-Asp-Tyr-Pro-Ser-Asn (SEQ ID NO:11); Cys-Lys-Thr-Tyr-Ser-Lys-Tyr-Cys-Xaa-Ala-Asp-Ser-Xaa- Cys-Cys-Thr-Xaa-Gln-Cys-Val-Arg-Ser-Tyr-Cys-Thr-Leu- Phe (SEQ ID NO:10) wherein Xaa is Gla and the C-terminus is amidated; His-Xaa-Xaa-Cys-Cys-Leu-Tyr-Gly-Lys-Cys-Arg-Arg-Tyr- Xaa-Gly-Cys-Ser- Ser-Ala-Ser-Cys-Cys-Gln (SEQ ID NO:9) wherein Xaa is 4Hyp; Gly-Cys-Cys-Ser-His-Pro-Ala-Cys-Ser-Gly-Lys-Tyr-Gln- Xaa-Tyr-Cys-Arg- Xaa- Ser (SEQ ID NO:8) wherein Xaa is Gla and the C-terminus is amidated; and Gly-Xaa-Ser-Phe-Cys-Lys-Ala-Asp-Glu-Lys-Xaa-Cys-Glu- Tyr-His-Ala-Asp-Cys-Cys-Asn-Cys-Cys-Leu-Ser-Gly-Ile- Cys-Ala-Xaa-Ser-Thr-Asn-Trp-Ile-Leu-Pro-Gly-Cys-Ser- Thr-Ser-Ser-Phe-Phe-Lys-Ile (SEQ ID NO:7) wherein Xaa is 4Hyp. These conotoxins may be used to prepare medicaments for the treatment of neuromuscular disorders. Some may be used for rapid reversible immobilisation of muscles or for diagnosing myasthenia gravis or Lambert-Eaton myasthenic syndrome.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2420184C |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
| title | CONOTOXINS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A20%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ABOGADIE,%20FE&rft.date=2004-09-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2420184C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |